Hermetica Superfood Encyclopedia
The Short Answer
Cyathus stercoreus produces cyathane diterpenoids (stercorins A–C) and polyketide-type antioxidants (cyathusals A–C) that promote neurite outgrowth in PC-12 cells and suppress neuroinflammatory NO production in microglial BV2 cells with IC₅₀ values of 1.64–9.25 µM. All evidence remains confined to in vitro cell culture models; no human clinical trials have been conducted, and no standardized supplemental dose or confirmed clinical benefit has been established.
CategoryMushroom
GroupMushroom/Fungi
Evidence LevelPreliminary
Primary KeywordCyathus stercoreus benefits
Cyathus stercoreus — botanical close-up
Health Benefits
**Antioxidant Activity**
Cyathusals A–C, polyketide-type compounds isolated from fermented fruiting body cultures, scavenge DPPH and ABTS free radicals via electron donation and hydrogen atom transfer, reducing oxidative burden in cell-based assays.
**Neuroprotective Potential**
Stercorins A–C at 10 µM enhance nerve growth factor (NGF)-induced neuritogenesis in PC-12 pheochromocytoma cells, suggesting a capacity to support neuronal differentiation and potentially slow neurodegenerative processes.
**Anti-Neuroinflammatory Effects**
Cyathane diterpenoids, including stercorin A (IC₅₀ 1.64 µM), stercorin B (IC₅₀ 9.25 µM), and stercorin C (IC₅₀ 8.71 µM), inhibit lipopolysaccharide-induced nitric oxide production in BV2 murine microglial cells, indicating suppression of pro-inflammatory signaling in the central nervous system.
**Rich Secondary Metabolite Diversity**
Over 185 secondary metabolites have been catalogued across bird's nest fungi including C. stercoreus, predominantly cyathane diterpenoids and drimane sesquiterpenoids, providing a broad chemical scaffold for pharmacological exploration.
**Antimicrobial Associations**
Alongside related Cyathus species documented in traditional Chinese medicine, C. stercoreus secondary metabolites have been associated with antimicrobial potential in ethnopharmacological literature, though specific activity data for this species remain limited.
**Sesquiterpenoid Bioactivity**
Stercorins D–E, drimane-type sesquiterpenoids isolated from liquid cultures, expand the structural repertoire of bioactive compounds in this species, with ongoing investigation into their pharmacological targets.
Origin & History
Natural habitat
Cyathus stercoreus is a saprotrophic basidiomycete fungus in the family Nidulariaceae, distributed globally across temperate and tropical regions, commonly found growing on dung, decaying wood, straw, and other nitrogen-rich substrates. It thrives in moist, shaded environments and has been documented across East Asia, North America, Europe, and parts of Africa, where decomposing organic matter provides its preferred growth medium. In research and biotechnology contexts, it is propagated via submerged liquid culture and fermented mycelium systems rather than traditional field cultivation, enabling controlled production of its secondary metabolites.
“Cyathus stercoreus and related bird's nest fungi have featured in traditional Chinese medicine as part of a broader pharmacopeia of medicinal fungi valued for their secondary metabolite richness and associations with antimicrobial and neuroprotective properties, though specific classical texts attributing defined therapeutic uses exclusively to C. stercoreus are not well-documented in the Western scientific literature. The genus Cyathus gained popular attention in East Asian ethnobotany primarily through C. striatus, with C. stercoreus recognized as a co-occurring species sharing similar morphological and chemical characteristics. Modern scientific interest in C. stercoreus began predominantly in the 2000s with the advent of high-resolution NMR spectroscopy and mass spectrometry enabling precise structural elucidation of complex terpenoids from small-scale fungal cultures. Traditional preparation, where practiced, involved decoctions or powdered dried fruiting bodies, though no standardized historical recipe specific to C. stercoreus has been formally recorded in accessible ethnopharmacological surveys.”Traditional Medicine
Scientific Research
The entire evidence base for Cyathus stercoreus consists of in vitro studies conducted in cell culture systems, with no animal models or human clinical trials published as of the available literature. Key studies have employed PC-12 rat adrenal pheochromocytoma cells and BV2 murine microglial cells to characterize neurotrophic and anti-neuroinflammatory activities of isolated stercorins A–C, reporting IC₅₀ values for NO inhibition in the 1.64–9.25 µM range; sample sizes are limited to experimental replicates without statistically powered cohorts. Antioxidant activity of cyathusals A–C has been demonstrated in DPPH and ABTS radical scavenging assays from fermented culture extracts, though specific IC₅₀ values were not quantified in available reports. The related species Cyathus striatus has marginally more pharmacological data, including a patent describing caspase-8/9-mediated apoptosis in pancreatic cancer cell lines, but these findings cannot be extrapolated to C. stercoreus, and the overall evidence quality for the genus remains strictly preliminary.
Preparation & Dosage
Traditional preparation
**Laboratory Extracts (Research Use Only)**
Methanol or ethyl acetate extracts from liquid-cultured mycelium or fermented fruiting bodies; no standardized extraction ratio established for human use.
**Submerged Mycelium Culture**
Primary research preparation method; yields cyathane diterpenoids and drimane sesquiterpenoids at concentrations sufficient for in vitro bioassay (tested at 10 µM in cell culture).
**Fermented Fruiting Body Extract**
Source of cyathusals A–C (polyketide antioxidants); prepared by solid-state or liquid fermentation followed by solvent partitioning.
**Human Supplemental Dose**
Not established; no dose-ranging, pharmacokinetic, or clinical efficacy studies exist to support a recommended daily intake.
**Standardization**
No commercial standardization benchmarks (e.g., percentage cyathane diterpenoids or cyathusal content) have been validated or adopted by any regulatory or industry body.
**Timing and Format**
Unknown; C. stercoreus is not currently available as a standardized nutritional supplement and is not used in mainstream nutraceutical formulations.
Nutritional Profile
Cyathus stercoreus has not been characterized for conventional macronutrient or micronutrient composition in the manner of edible culinary mushrooms; it is not consumed as a food source due to its dung-associated growth habitat and small, inedible fruiting body morphology. Its nutritional relevance is entirely phytochemical: the primary bioactive classes are cyathane diterpenoids (stercorins A–E), polyketide-type phenolics (cyathusals A–C), and drimane sesquiterpenoids, all present in trace quantities in naturally occurring fruiting bodies and enriched only through controlled liquid culture fermentation. Over 185 secondary metabolites have been catalogued across the Cyathus genus, with cyathane diterpenoids representing the dominant and most pharmacologically characterized class. Bioavailability of these lipophilic terpenoids in humans is entirely unstudied; structural features suggesting moderate lipophilicity imply potential for passive intestinal absorption, but no in vivo pharmacokinetic data exist to confirm this.
How It Works
Mechanism of Action
Stercorins A–C, cyathane diterpenoids bearing a bicyclo[6.3.0] carboskeleton (stercorin A featuring an unusual 4,9-seco-carbon rearrangement), potentiate NGF-induced signaling in PC-12 cells at 10 µM, likely by modulating downstream TrkA receptor pathways that regulate cytoskeletal reorganization and axonal outgrowth. In BV2 microglial cells challenged with LPS, these same compounds inhibit inducible nitric oxide synthase (iNOS)-dependent NO production, suggesting interference with NF-κB or MAPK inflammatory cascades at submicromolar to low-micromolar concentrations. Cyathusals A–C exert antioxidant effects through direct radical quenching mechanisms—electron donation and hydrogen atom transfer—neutralizing DPPH and ABTS radical species, which reduces oxidative stress without requiring enzymatic co-factors. Collectively, these mechanisms position C. stercoreus metabolites as multi-target agents acting at the intersection of neurotrophin signaling, innate immune modulation, and reactive oxygen species homeostasis, though all pathway data are inferred from cell-free or single-cell-line assays.
Clinical Evidence
No clinical trials investigating Cyathus stercoreus in human subjects have been identified in the published literature or registered trial databases. Outcomes such as cognitive function, neuroinflammatory biomarkers, oxidative stress indices, or safety endpoints have not been evaluated in any structured human study. The absence of pharmacokinetic data, bioavailability measurements, and dose-escalation studies means that effective or safe human doses remain entirely unknown. Confidence in any health claim for C. stercoreus is therefore very low; all assertions of benefit are hypothesis-generating and derived exclusively from reductionist in vitro models.
Safety & Interactions
No human safety data, toxicological studies, adverse event reports, or maximum tolerated dose information are available for Cyathus stercoreus or its isolated compounds in any published clinical or preclinical in vivo context. In vitro studies at active concentrations (10 µM for neurotrophic effects; 1.64–9.25 µM for anti-inflammatory effects) did not report overt cytotoxicity to PC-12 or BV2 cells, suggesting low acute cellular toxicity at these concentrations, but this cannot be extrapolated to systemic human safety. No drug interaction data exist; theoretical caution is warranted regarding co-administration with anti-inflammatory agents, neuroprotective drugs, or antioxidant therapies given mechanistic overlap at iNOS and NF-κB pathways, though no empirical interaction data support specific warnings. Use during pregnancy or lactation is not recommended due to the complete absence of safety evaluation; individuals with mushroom allergies or immunocompromised states should exercise additional caution given the fungal origin of this ingredient.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Cyathus stercoreus (Schwein.) De Tonibird's nest fungusdung bird's nest fungusNidularia stercoreus
Frequently Asked Questions
What are the main bioactive compounds in Cyathus stercoreus?
The primary bioactive compounds are cyathane diterpenoids called stercorins A–C (with stercorin A featuring an unusual 4,9-seco-carbon skeleton), polyketide-type antioxidants called cyathusals A–C, and drimane sesquiterpenoids (stercorins D–E). These metabolites have been isolated from liquid mycelium cultures and fermented fruiting bodies and tested for neurotrophic, anti-neuroinflammatory, and radical-scavenging activities in cell-based assays.
Is there any clinical evidence that Cyathus stercoreus works in humans?
No clinical trials involving human subjects have been published for Cyathus stercoreus; all available evidence comes from in vitro cell culture experiments using PC-12 neuronal cells and BV2 microglial cells. While these studies report meaningful activity at low micromolar concentrations (IC₅₀ as low as 1.64 µM for NO inhibition), the translation of these findings to human efficacy and safety has not been investigated.
What is the recommended dosage of Cyathus stercoreus supplement?
No established human supplemental dose exists for Cyathus stercoreus; it is not currently available as a standardized commercial supplement, and no pharmacokinetic or dose-ranging studies in humans have been conducted. Research has only tested isolated compounds at 10 µM in cell culture systems, which cannot be directly converted to a human oral dose without in vivo pharmacokinetic data.
How does Cyathus stercoreus support neuroprotection?
Stercorins A–C promote NGF-induced neurite outgrowth in PC-12 cells at 10 µM, suggesting these cyathane diterpenoids can potentiate neurotrophin signaling pathways involved in neuronal differentiation and survival. Additionally, the same compounds inhibit LPS-induced nitric oxide production in BV2 microglial cells with IC₅₀ values of 1.64–9.25 µM, indicating suppression of neuroinflammatory iNOS activity that contributes to neurotoxicity in diseases like Alzheimer's.
Is Cyathus stercoreus safe to consume?
Safety in humans has not been evaluated; no toxicology studies, adverse event reports, or maximum safe dose determinations exist for C. stercoreus or its isolated compounds in clinical or animal models. In vitro data show low cellular toxicity at pharmacologically active concentrations, but systemic safety, drug interactions, and suitability during pregnancy or lactation remain entirely unknown, making cautious avoidance the prudent approach until proper safety data are generated.
How does Cyathus stercoreus compare to other medicinal mushrooms for antioxidant support?
Cyathus stercoreus contains unique polyketide compounds (cyathusals A–C) that demonstrate antioxidant activity through multiple mechanisms including DPPH and ABTS free radical scavenging via electron donation and hydrogen atom transfer. While other medicinal mushrooms like reishi and cordyceps offer antioxidant benefits, Cyathus stercoreus's specific bioactive profile and fermentation-derived compounds distinguish its potential mechanism of action. Direct comparative efficacy studies between Cyathus stercoreus and other mushroom species remain limited in published literature.
Who may benefit most from Cyathus stercoreus supplementation?
Individuals seeking neuroprotective support or antioxidant defense may benefit most from Cyathus stercoreus, particularly given its demonstrated ability to enhance nerve growth factor (NGF)-induced neuritogenesis in cell studies. Those experiencing oxidative stress-related concerns or interested in cognitive and neurological wellness represent potential target populations. However, optimal candidacy should be determined through consultation with a healthcare provider, as research in human populations remains limited.
What is the difference between wild-harvested and fermented Cyathus stercoreus extracts?
Fermented fruiting body cultures of Cyathus stercoreus are the primary source of the well-characterized bioactive compounds cyathusals A–C and stercorins A–C that demonstrate antioxidant and neuroprotective activity in research. Fermentation appears to enhance or concentrate these polyketide-type compounds compared to standard mushroom preparations. Wild-harvested material has not been extensively characterized for its bioactive content or standardized for supplement use.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w cyathus-stercoreus-birds-nest-fungus curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
